SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Pierre Le Moyne d'Iberville — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPierre Le Moyne d'Iberville
Date of birth1661-07-16
IdentifiersMRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260
Document date1705-03-03
AuthorMarguerite Delacroix-Boateng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week follow-up of recurrent fevers, seen the same day in infectious diseases. [S]

History of Present Illness

Mr. Le Moyne d'Iberville returns two weeks after his first visit, on the day of his infectious diseases consultation with Dr. Okonkwo-Hale. He has had no fever, chills or sweats since then. The intake blood smears and rapid antigen test were negative, and the PCR sent to the reference laboratory at intake has detected Plasmodium vivax DNA. His quantitative G6PD activity is normal. He is not on any medicine and has no allergies. He is keen to be treated before the squadron's preparations take up all his time. [S]

ElementDetail
FeverNone since intake
ResultsSmears and rapid antigen test negative; PCR detected P. vivax DNA; G6PD normal
MedicinesNone

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, chills or sweats; tired at the end of the day
GastrointestinalNegativeNo abdominal pain or jaundice
GenitourinaryNegativeNo dark urine

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total)Oral route1705-03-03 to 1705-03-05completedS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days30 mg base once daily for 14 daysOral route1705-03-03 to 1705-03-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1705-03-03Body height175cmS
1705-03-03Body weight68.6kgS
1705-03-03Body mass index (BMI) [Ratio]22.4kg/m2S
1705-03-03Systolic blood pressure122mm[Hg]S
1705-03-03Diastolic blood pressure76mm[Hg]S
1705-03-03Heart rate68/minS
1705-03-03Respiratory rate14/minS
1705-03-03Body temperature36.6CelS
1705-03-03Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1705-03-03; see the Vital Signs section. [S]

SystemFinding
GeneralWell; temperature 36.6 C, blood pressure 122/76, pulse 68, weight 68.6 kg
EyesSclerae white; mild conjunctival pallor
AbdomenSpleen tip not palpable; liver not enlarged

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requestedresolvedconfirmed R50.9S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation.
Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PDactiveconfirmed B51.9S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic.
Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccinesactiveconfirmed Z71.84S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryMalaria diagnosis: smears, rapid antigen test and species PCRAt diagnosisCompleted todaySmears and rapid antigen test negative at intake; PCR from the intake sample detected P. vivax DNA
LaboratoryQuantitative G6PD activity before primaquine or tafenoquineOnce, before an 8-aminoquinolineCompleted today11.8 U/g Hb at intake, normal
LaboratoryBlood count and bilirubin for hemolysis on primaquineBaseline, then after the courseUp to dateHemoglobin 13.0 g/dL, platelets 141 x10^3/uL and bilirubin 1.1 mg/dL at intake; repeat after primaquine
ReferralInfectious diseases (travel medicine) consultationOnceCompleted todaySeen by Dr. Okonkwo-Hale today
Medication safetyAdverse effects: nausea, abdominal pain, dark urine, breathlessness, cyanosisDuring the courseCompleted todayCounseled before the first doses; take with food
Self-managementRelapse surveillance and the fever action planEvery visitCompleted todayFever card given: a smear the same day for any fever
LaboratoryFollow-up blood smear after treatment (ideally within one week of finishing)About one week after finishingOrderedSmear and PCR ordered for a week after the last primaquine dose

Goal progress:

Guideline basis: Treatment of Uncomplicated Malaria (clinical guidance) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006)

Follow-up: Review in four weeks. Next scheduled visit 1705-03-31: six-week review after chloroquine and primaquine: blood count, adverse effects, relapse surveillance. [S]